The document is a regulatory filing containing the transcript of the Q2 FY27 Earnings Conference Call held on Monday, November 2, 2026, at 5:00 PM IST.
The stated purpose of the event was to discuss the company's Q2 & H1 FY27 financial performance and business outlook.
The meeting was held after the earnings announcement, as it is a post-results investor interaction.
Management participants from the senior team included:
Mr. Anurag Surana, Non-Executive Chairman
Dr. Harin Kanani, Managing Director
Mr. Gopikrishnan Sarathy, Chief Financial Officer
The transcript was made available on the company's website and filed with the stock exchanges. A standard disclaimer was read, noting that certain statements may be forward-looking and actual results may vary.
The company did not indicate that no unpublished price sensitive information (UPSI) would be shared; instead, the call included detailed operational and financial updates.
Financial Highlights & Guidance References
The period discussed is Q2 FY27 (Quarter ended September 30, 2026) and H1 FY27.
Consolidated Financials for Q2 FY27:
Revenue: INR 296 crore (up 42% YoY)
EBITDA: INR 45 crore (up 51% YoY)
PAT: INR 8 crore (up 144% YoY)
Standalone Financials for Q2 FY27:
Revenue: INR 288 crore
EBITDA: INR 54 crore (up 54% YoY) with a margin of 18.6%
Base Business (Standalone) FY28 Guidance: Revenue expected to be INR 1,200-1,300 crore.
FY28 Net Debt Guidance: Expected to be in the range of INR 1,300-1,500 crore.
Strategic & Operational Updates
Organolithium Capacity Expansion: The Board approved doubling the Organolithium manufacturing capacity from 300 MTPA to 600 MTPA at the Patancheru, Telangana facility. The estimated capital outlay is up to INR 45 crore, expected to be completed by H1 FY28 (September 2027). This expansion is projected to unlock an additional revenue potential of INR 150-200 crore.
Maiden QIP: Successfully completed a Qualified Institutional Placement (QIP) raising INR 600 crore, which was oversubscribed 6.5x. The proceeds are being used to deleverage the balance sheet.
Insurance Claims: Cumulative recoveries to date stand at INR 164 crore (INR 155 crore on account payments + INR 9 crore from salvage). An additional claim amount of INR 152 crore was accepted from the insurer on October 29, 2026, bringing the total on-account claims received and receivable to INR 316 crore.
Dahej Plant Rebuild: Trial runs of the rebuilt Dahej plant are underway, with commercial production expected to commence shortly within FY27 (likely in Q3 or Q4).
Credit Rating Upgrade: CRISIL revised the outlook on Neogen's long-term bank facility to 'CRISIL A- Stable' from 'Negative' and reaffirmed the short-term rating at 'CRISIL A2+'.
Battery Chemicals Progress:
Electrolyte Salts: Secured provisional approvals from five major international customers; completed final site audits for three US-based manufacturers; commenced commercial supply with two international customers.
Electrolyte: Mechanical assembly is complete; trial runs have begun alongside facility validation and active joint trials of recipes with multiple Giga factories.
Business Transfer: Neogen Ionics executed a business transfer agreement to consolidate the lithium-ion electrolyte salt undertaking under its step-down subsidiary, Neogen Morita New Materials Limited (NML), for a cash consideration of INR 245 crore.
Working Capital: Inventory days increased due to the Dahej plant rebuild and toll manufacturing arrangements. The company is targeting to reduce inventory days to ~180 by end-FY27 and to 140-160 days in FY28.
Additional Notes Section
The document is an enclosure to a regulatory filing submitted to the BSE and NSE. The enclosed transcript was also uploaded on the company's website.
The announcement itself did not disclose any financial data; the financial figures and strategic commentary are contained within the enclosed transcript of the earnings call.
The transcript includes a full Q&A session with analysts covering details on capacity expansion, demand outlook, customer approvals, capex plans, and margin guidance.
